Deal Notes: GlycoMimetics/Pfizer, Pharmacyclics/Servier, TG Therapeutics/Rhizen, Takeda/BioMotiv, Amherst/NovaDel
This article was originally published in Scrip
Pfizer delays Phase III study with GlycoMimetics drug; Pharmacyclics, Servier end agreement; TG Therapeutics licenses drug from Rhizen; Takeda invests $25m in BioMotiv; and Amherst buys NovaDel's ZolpiMist.
You may also be interested in...
Warning letter objects to webpage and meeting exhibit material for excluding any risk information and suggesting mist formulation is superior to oral zolpidem products.
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.